

Familial Breast Cancer Advisory Committee Interests Register

Register last updated: 05/01/26

All interests have been signed off by the Chair and the NICE Developer Lead

Name	Role on the committee	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Alison Cameron	Committee member - Chair	Direct-financial	Consultant Clinical Oncologist, University Bristol and Weston NHS Foundation Trust.	06/07	03/25	Ongoing	Declare and participate Salaried employment in the NHS
Alison Cameron	Committee member - Chair	Direct, non-financial professional and personal	I am a member of the Royal College of Radiologists Society Training Board and curriculum committee. This role is unpaid. This is not directly related to the guideline, but we may have teaching sessions related to this content.	2021	03/25	Ongoing	Non-specific Declare and participate
Alison Cameron	Committee member - Chair	Direct, non-financial professional and personal	I am a Royal College of Radiologists e-learning lead for Clinical Oncology. This role is unpaid. This is not directly related to the guideline, but we may have teaching sessions related to this content.	12/24	03/25	Ongoing	Non-specific Declare and participate

Kayleigh Davies-Crowley	Committee member – Advanced Nurse Practitioner	Direct-financial	Breast Advanced Nurse Practitioner, Royal Liverpool Hospital.	08/14	05/25	Ongoing	Declare and participate Salaried employment in the NHS
Kayleigh Davies-Crowley	Committee member – Advanced Nurse Practitioner	Direct, non-financial professional and personal	Nurse member on the education and training committee for the Association of Breast Surgery. This role is unpaid.	05/25	05/25	Ongoing	Non-specific Declare and participate
Kayleigh Davies-Crowley	Committee member – Advanced Nurse Practitioner	Direct, non-financial professional and personal	Davies-Crowley K, Brooks R. Expanding role of the breast advanced nurse practitioner: mainstream pathway for genetic testing . Br J Nurs. 2025 May 22;34(10):S26-S30. doi: 10.12968/bjon.2024.0474. PMID: 40396950.	05/25	05/25	05/25	Non-specific Declare and participate
Kayleigh Davies-Crowley	Committee member – Advanced Nurse Practitioner	Direct, non-financial professional and personal	Potter S, Fairhurst K, Cowan K, Vincent S, Lewis I, Cutress RI, Stobart H, Fairbrother P, Turner S, Davies-Crowley K, Jeevan R, Rattay T, O'Connell R, Bundred N, McIntosh SA. Identifying research priorities in breast cancer surgery: a UK priority setting	11/22	05/25	11/22	Non-specific Declare and participate

			<p>partnership with the James Lind Alliance, Breast Cancer Res Treat. 2023 Jan;197(1):39-49. doi: 10.1007/s10549-022-06756-4. Epub 2022 Nov 1. PMID: 36319906; PMCID: PMC9628302.</p>				
Kayleigh Davies-Crowley	Committee member – Advanced Nurse Practitioner	Direct, non-financial professional and personal	<p>Service evaluation of newly established breast mainstream genetic R208 panel testing undertaken at liverpool university hospital foundation trust (LUHFT)</p> <p>Davies-Crowley, Kayleigh, Brooks, Rebecca</p> <p>European Journal of Surgical Oncology, Volume 51, 109818</p> <p>DOI: 10.1016/j.ejso.2025.109818</p>	05/25	05/25	05/25	Non-specific Declare and participate
Kayleigh Davies-Crowley	Committee member – Advanced Nurse Practitioner	Direct, non-financial professional and personal	<p>Outcomes of advice and guidance referrals to a large breast surgery service</p> <p>Lennon, Hannah et al.</p>	05/24	05/25	05/24	Non-specific Declare and participate

			May 2024 European Journal of Surgical Oncology 50:108134 DOI: 10.1016/j.ejso.2024.108134				
Rachael Griffin	Co-opted member – Lay member	Direct-financial	I work for a company (Jazz Pharmaceuticals) that runs clinical trials. Some in breast cancer as they are trials for the drug Zanidatamab. However, I am not involved in the trials themselves. I work in Clinical Outsourcing - overseeing our 3rd party suppliers.	04/22	07/25	Ongoing	Non-specific Declare and participate
Helen Hanson	Committee member - Clinical Geneticist	Direct, non-financial professional and personal	UK Cancer Genetics Group (UKCGG): Chair of UKCGG (Term 2021-2024) - retiring Chair May 2024-2025. Led on improving access and consistency of care of patients with rare inherited predisposition syndrome. I received no payment or honorarium for this role	01/23	03/25	05/25	Non-specific Declare and participate

			other than travel expenses.				
Helen Hanson	Committee member - Clinical Geneticist	Direct, non-financial professional and personal and indirect-financial	<p>Co-investigator on "CanGene-CanVar" a 5-year £4.3 million Cancer Research UK catalyst award-funded programme. (Sept 2019 –March 2025) as part of Work Package 3 :Translation and implementation of Clinical Guidelines.</p> <p>Research monies went to my institution.</p> <p>During this time I have co-authored and published a number of papers on recommended clinical management of individuals with inherited cancer predisposition, including those with a predisposition to breast cancer. Those relevant to breast cancer are included below.</p>	09/19	03/25	03/25	Specific Declare and participate Individual papers assessed below.
Helen Hanson	Committee member - Clinical Geneticist	Direct, non-financial professional and personal	Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the	01/25	03/25	01/25	Specific Declare and participate

			<p><u>American College of Medical Genetics and Genomics (ACMG)</u>. Pal T, Schon KR, Astiazaran-Symonds E, Balmaña J, Foulkes WD, James P, Klugman S, Livinski AA, Mak JS, Ngeow J, Voian N, Wick MJ, Hanson H, Stewart DR, Tischkowitz M; ACMG Professional Practice and Guidelines Committee. <i>Genet Med.</i> 2025 Jan;27(1):101243. doi: 10.1016/j.gim.2024.101243. PMID: 39636577</p>				Despite being specific to the topic under consideration this paper would not be included in the evidence base.
Helen Hanson	Committee member - Clinical Geneticist	Direct, non-financial professional and personal	<p><u>Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.</u> Rowlands CF, Allen S, Balmaña J, Domchek SM, Evans DG, Hanson H, Hoogerbrugge N, James PA, Nathanson KL, Robson M, Tischkowitz M, Foulkes WD, Turnbull C. <i>Ann Oncol.</i> 2024 Oct;35(10):892-901. doi: 10.1016/j.annonc.2024.07.244. PMID: 38986768.</p>	10/24	03/25	10/24	Non-specific Declare and participate

Helen Hanson	Committee member - Clinical Geneticist	Direct, non-financial professional and personal	<u>Digital innovation for cancer risk assessment allows large-scale service redevelopment of regional cancer genetics service delivery.</u> Youngs A, Forman A, Elms M, Kohut K, Hlaing MT, Short J, Hanson H, Snape K. Fam Cancer. 2024 Nov;23(4):591-598. doi: 10.1007/s10689-024-00407-x. PMID: 38954285;	11/24	03/25	11/24	Non-specific Declare and participate
Helen Hanson	Committee member - Clinical Geneticist	Direct, non-financial professional and personal	<u>Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice.</u> Tsoulaki O, Tischkowitz M, Antoniou AC, Musgrave H, Rea G, Gandhi A, Cox K, Irvine T, Holcombe S, Eccles D, Turnbull C, Cutress R; Meeting Attendees; Archer S, Hanson H.. Br J Cancer. 2024 Jun;130(12):2027-2036. doi: 10.1038/s41416-024-02733-4. PMID: 38834743	06/24	03/25	06/24	Specific Declare and participate Despite being specific to the topic under consideration this paper would not be included in the evidence base for the review questions in the update.

Helen Hanson	Committee member - Clinical Geneticist	Direct, non-financial professional and personal	<u>Breast cancer risk assessment for prescription of menopausal hormone therapy in women with a family history of breast cancer: an epidemiological modelling study.</u> Huntley C, Torr B, Kavanaugh G, George A, Hanson H, Snape K, Broggio J, Glasgow L, Tischkowitz M, Evans DG, Antoniou AC, Turnbull C. Br J Gen Pract. 2024 Aug 29;74(746):e610-e618. doi: 10.3399/BJGP.2023.0327. PMID: 38724186	08/24	03/25	08/24	Non-specific Declare and participate
Helen Hanson	Committee member - Clinical Geneticist	Direct, non-financial professional and personal	<u>EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer</u> McDevitt T, Durkie M, Arnold N, Burghel GJ, Butler S, Claes KBM, Logan P, Robinson R, Sheils K, Wolstenholme N, Hanson H, Turnbull C, Hume S. Eur J Hum Genet. 2024 Mar 5. doi:	03/24	03/25	03/24	Specific Declare and participate Despite being specific to the topic under consideration this paper would not be included in the evidence base for the review questions in the update.

			10.1038/s41431-023-01507 PMID: 38443545				
Helen Hanson	Committee member - Clinical Geneticist	Direct, non-financial professional and personal	<p><u>UK recommendations for the management of transgender and gender-diverse patients with inherited cancer risks</u></p> <p>Giblin J, Coad B, Lamb C, Berlin C, Rea G, Hanson H, Snape K, Berner A; Consensus Meeting attendees. BJC Rep. 2023 Jun 22;1(1):1. doi: 10.1038/s44276-023-00002-0. PMID: 39516684;</p>	06/22	03/25	06/22	<p>Specific</p> <p>Declare and participate</p> <p>Despite being specific to the topic under consideration this paper would not be included in the evidence base for the review questions in the update.</p>
Helen Hanson	Committee member - Clinical Geneticist	Direct, non-financial professional and personal	<p><u>Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics</u></p> <p>(ACMG). Hanson H, Astiazaran Symonds, M. Amendola L, Balmaña J, Foulkes W, James P, Klugman S, Ngeow J, Schmutzler R, Voian N, Wick M, Pal T, Tischkowitz M, Stewart D; on behalf of</p>	10/23	03/25	10/23	<p>Specific</p> <p>Declare and participate</p> <p>Despite being specific to the topic under consideration this paper would not be included in the evidence base for the review questions in the update.</p>

			the ACMG Professional Practices and Guidelines Committee. <i>Genet Med.</i> 2023 Oct;25(10):100870. doi: 10.1016/j.gim.2023.100870. PMID: 37490054				
Helen Hanson	Committee member - Clinical Geneticist	Direct, non-financial professional and personal	<p><u>UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2.</u> Hanson H, Kulkarni A, Loong L, Kavanaugh G, Torr B, Allen S, Ahmed M, Antoniou AC, Cleaver R, Dabir T, Evans DG, Golightly E, Jewell R, Kohut K, Manchanda R, Murray A, Murray J, Ong KR, Rosenthal AN, Woodward ER, Eccles DM, Turnbull C, Tischkowitz M; Consensus meeting attendees, Laloo F. <i>J Med Genet.</i> 2022 Nov 21:jmg-2022-108898. doi: 10.1136/jmg-2022-108898. PMID: 36411</p>	11/22	03/25	11/22	<p>Specific Declare and participate Despite being specific to the topic under consideration this paper would not be included in the evidence base for the review questions in the update.</p>

Helen Hanson	Committee member - Clinical Geneticist	Direct-financial	Consultant in Cancer Genetics, Royal Devon University Healthcare NHS Foundation Trust	09/23	03/25	Ongoing	Declare and participate Salaried employment in the NHS
Helen Hanson	Committee member - Clinical Geneticist	Direct-financial	Associate Professor Clinical Cancer Genetics, University of Exeter Medical School	09/23	03/25	Ongoing	Declare and participate Salaried employment
Helen Hanson	Committee member - Clinical Geneticist	Direct, non-financial professional and personal	Christopher J, Edgerley K, McIldowie B, Jewell R, Kemp Z, Snape K, Hanson H; Consensus meeting attendees. Recontact and follow-up for individuals with germline pathogenic variants in hereditary breast and ovarian cancer susceptibility genes: a UK Cancer Genetics Group consensus meeting. <i>J Med Genet</i> . 2025 Oct 1:jmg-2025-110979. doi: 10.1136/jmg-2025-110979. Epub ahead of print. PMID: 41159931.	10/25	01/26		Non-specific Declare and participate
Sadaf Haque	Committee member – General Practitioner	Direct-financial	Salaried General Practitioner, Rosebank Health Primary Care Network, Gloucester	2017	06/25	Ongoing	Declare and participate Salaried employment in the NHS

Sadaf Haque	Committee member – General Practitioner	Direct-financial	Clinical Lead Cancer, NHS Gloucestershire	2013	06/25	Ongoing	Declare and participate Salaried employment in the NHS
Sadaf Haque	Committee member – General Practitioner	Direct-financial	Breast Physician, Gloucestershire Hospitals NHS Foundation Trust	2022	06/25	Ongoing	Declare and participate Salaried employment in the NHS
Sadaf Haque	Committee member – General Practitioner	Direct-financial	Chair Gloucestershire GP Education Trust - this is a membership charitable organisation offering aspirational GP education with local provider colleagues and as Education Programme Director and Honorary Tutor I take an active role in forming policy/ strategy and planning/ facilitating educational events. I kite-mark all GGPET education sessions for quality of GP education. I attend NHS Gloucestershire's monthly HEE Training Hub meetings.	2013	06/25	Ongoing	Declare and participate Salaried employment in non-profitable organisation
Sadaf Haque	Committee member – General Practitioner	Direct-financial	Gloucestershire LMC Medical Executive I am an appointed salaried officer of the LMC serving	11/25	12/25	Ongoing	Non-specific Declare and participate

			in an non-voting capacity and cannot hold elected officer position on the Gloucestershire Committee. I provide professional support to the Gloucestershire local Committee, dedicate time to LMC matters, and keep the Committee informed of local, regional, and national issues.				
Ashley Hurst	Committee member – Lay member	Direct, non-financial professional and personal	Member of NICRCF (Northern Ireland Cancer Research Consumer Forum)		06/25		Non-specific Declare and participate
Ashley Hurst	Committee member – Lay member	Direct, non-financial professional and personal	PPI Member of NiCAN Breast CRG (Northern Ireland Cancer Network Breast Clinical Reference Group).		06/25		Non-specific Declare and participate
Zoe Kemp	Committee member - Clinical Geneticist	Direct-financial	Consultant in Cancer Genetics and Breast Medical Oncology, Royal Marsden Hospital	12/12	03/25	Ongoing	Declare and participate Salaried employment in the NHS
Zoe Kemp	Committee member - Clinical Geneticist	Direct-financial	Private practice at Royal Marsden, 2 hours per week (approximately 6% of my overall practice is private). This includes	04/21	03/25	Ongoing	Declare and participate Private practice represents 6% of overall practice.

			germline genetic testing primarily for breast cancer patients.				
Zoe Kemp	Committee member - Clinical Geneticist	Indirect-financial	I work one day a week on an NHS Transformation programme for genetic testing in breast cancer patients. This research day is with the Institute for Cancer Research and is funded by an SBRI Healthcare grant. Research funding goes to the institute.	2024	03/25	03/25	Specific Declare and participate Open declaration is sufficient mitigation
Zoe Kemp	Committee member - Clinical Geneticist	Direct-financial	I gave an educational talk for Pfizer and received honorarium. The presentation was on germline testing for breast cancer patients and which patients were eligible under the National Test Directory.	2024	03/25	2024	Specific Declare and participate Reimbursement is reasonable in return of expertise.
Zoe Kemp	Committee member - Clinical Geneticist	Direct, non-financial professional and personal	Attendance at the San Antonio Breast Cancer Symposium 9-12 December 2025. I am not presenting however I am an author on an accepted poster. All expenses to	12/25	11/25	12/25	Non-specific Declare and participate

			attend have been covered personally.				
Zoe Kemp	Committee member - Clinical Geneticist	Direct, non-financial professional and personal	Christopher J, Edgerley K, McIldowie B, Jewell R, Kemp Z, Snape K, Hanson H; Consensus meeting attendees. Recontact and follow-up for individuals with germline pathogenic variants in hereditary breast and ovarian cancer susceptibility genes: a UK Cancer Genetics Group consensus meeting. <i>J Med Genet.</i> 2025 Oct 1:jmg-2025-110979. doi: 10.1136/jmg-2025-110979. Epub ahead of print. PMID: 41159931.	10/25	01/26		Non-specific Declare and participate
Sarah Pugh	Committee member – Genetic Counsellor	Direct-financial	Consultant Genetic Counsellor, Manchester Centre for Genomic Medicine	08/21	07/25	Ongoing	Declare and participate Salaried employment in the NHS
Sarah Pugh	Committee member – Genetic Counsellor	Direct, non-financial professional and personal	Woodward ER, Laloo F, Forde C, Pugh S, Burghel GJ, Schlecht H, Harkness EF, Howell A, Howell SJ, Gandhi A, Evans DG. Germline testing of BRCA1, BRCA2, PALB2 and CHEK2 c.1100delC in	03/24	07/25		Non-specific Declare and participate

			1514 triple negative familial and isolated breast cancers from a single centre, with extended testing of ATM, RAD51C and RAD51D in over 400. J Med Genet. 2024 Mar 21;61(4):385-391. doi: 10.1136/jmg-2023-109671 . PMID: 38123987.				
Sarah Pugh	Committee member – Genetic Counsellor	Direct, non-financial professional and personal	Evans DG, Burghel GJ, Howell SJ, Pugh S, Forde C, Howell A, Laloo F, Woodward ER. Pathogenic variant detection rate varies considerably in male breast cancer families and sporadic cases: minimal additional contribution beyond BRCA2, BRCA1 and CHEK2. J Med Genet. 2024 Aug 29;61(9):853-855. doi: 0.1136/jmg2023-109826 . PMID: 38609177; PMCID: PMC11420751	08/24	07/25		Non-specific Declare and participate
Sarah Pugh	Committee member – Genetic Counsellor	Direct, non-financial professional and personal	Sodde P, Hyder Z, Pugh S, Laloo F, Martin R, Soh C, Naqvi J, Whitehouse R, Evans DG, Woodward ER. Evaluation of whole-body MRI for cancer early	06/25	07/25		Specific Declare and participate

			detection in Li-Fraumeni syndrome. <i>J Med Genet.</i> 2025 Jun 30:jmg-2025-110704. doi: 10.1136/jmg-2025-110704 . Epub ahead of print. PMID: 40588398.				Keep under review based on the topic under consideration.
Sarah Pugh	Committee member – Genetic Counsellor	Direct, non-financial professional and personal	Evans DG, Morgan RD, Forde C, Crosbie EJ, Burghel GJ, Pugh S, Gandhi A, Howell A, Howell SJ, Woodward ER, Laloo F. Validation of the pathology-adjusted Manchester scoring system in over 10 000 assessments of cases with breast and/or ovarian cancer. <i>J Med Genet.</i> 2025 Nov 19:jmg-2025-110869. doi: 10.1136/jmg-2025-110869 . Epub ahead of print. PMID: 41260924.	11/25	12/25		Specific Declare and participate Keep under review while included studies are identified for RQ1 on diagnostic risk tools.
Sarah Pugh	Committee member – Genetic Counsellor	Direct, non-financial professional and personal	Member of consensus group / not co-author: Christopher J, Edgerley K, McIldowie B, Jewell R, Kemp Z, Snape K, Hanson H; Consensus meeting attendees. Recontact and follow-up for individuals with germline pathogenic variants in hereditary	10/25	12/25		Non-specific Declare and participate

			breast and ovarian cancer susceptibility genes: a UK Cancer Genetics Group consensus meeting. <i>J Med Genet.</i> 2025 Oct 1:jmg-2025-110979. doi: 10.1136/jmg-2025-110979. Epub ahead of print. PMID: 41159931.				
Kathryn Rigby	Committee member – Breast Surgeon	Direct-financial	Consultant Oncoplastic Breast Surgeon – Doncaster & Bassetlaw Teaching Hospitals NHS Trust	2012	06/25	Ongoing	Declare and participate Salaried employment in the NHS
Kathryn Rigby	Committee member – Breast Surgeon	Non-financial professional and personal	Member of Association of Breast Surgery Clinical Standards and Practice committee, as a regional representative and then communications representative. We review and publish guidance/information on relevant topics for ABS members, clinical and non-clinical.	2017	06/25	Ongoing	Non-specific Declare and participate
Tamsin Sargeant	Committee member – Lay member	Direct, non-financial professional and personal	I'm a volunteer for Breast Cancer Now and I offer telephone and email support to women around their breast cancer	2013	05/25	Ongoing	Non-specific Declare and participate

			diagnosis, including familial breast cancer.				
Hannah Seabrook	Committee member – Clinical Psychologist	Direct-financial	I currently work as a Consultant Clinical Psychologist within the NHS in an Oncology Service that offers risk reducing mastectomy assessments for University Hospitals Coventry and Warwickshire NHS Trust.	06/18	05/25	Ongoing	Declare and participate Salaried employment in the NHS
Liz Sherwin	Committee member – Clinical Oncologist	Direct-financial	Consultant Clinical Oncologist, Ipswich Hospital	03/03	07/25	Ongoing	Declare and participate Salaried employment in the NHS
Liz Sherwin	Committee member – Clinical Oncologist	Direct-financial	Clinical Director for Oncology and Haematology across East Sussex and North Essex NHS Foundation Trust. Includes Chair of rapid decision group for chemotherapy prescribing in Trust wide electronic patient record and member of multidisciplinary cross-site genomics meeting establishing genetic and genomic testing pathways.	09/21	07/25	Ongoing	Declare and participate Salaried employment in the NHS

Liz Sherwin	Committee member – Clinical Oncologist	Direct-financial	Clinical Lead, Oncology	03/19	07/25	Ongoing	Declare and participate Salaried employment in the NHS
Liz Sherwin	Committee member – Clinical Oncologist	Direct-financial	Payment to attend ESMO Breast 2024	05/24	07/25		Specific Declare and participate Attendance at conference.
Liz Sherwin	Committee member – Clinical Oncologist	Direct-financial	Payment to chair meeting for Novartis to discuss breast cancer treatment (use of Ribociclib for advanced breast cancer). Not relevant to topic under consideration.	12/24	07/25		Non-specific Declare and participate
Liz Sherwin	Committee member – Clinical Oncologist	Direct-financial	Payment to chair meeting for Novartis discussing breast cancer treatment (use of Ribociclib for advanced breast cancer). Not relevant to topic under consideration.	10/23	07/25		Non-specific Declare and participate
Liz Sherwin	Committee member – Clinical Oncologist	Direct-financial	Payment to chair meeting for Novartis (use of Ribociclib for advanced breast cancer). Relevant to breast cancer but not topic under consideration.	08/23	07/25		Non-specific Declare and participate

Liz Sherwin	Committee member – Clinical Oncologist	Direct-financial	Payment to chair meeting for Novartis. Relevant to breast cancer but not topic under consideration.	02/23	07/25		Non-specific Declare and participate
Liz Sherwin	Committee member – Clinical Oncologist	Direct-financial	Payment to attend meeting to discuss breast cancer by Daachi Sanyo. This relates to use of Enhertu for metastatic Her 2 positive breast cancer.	04/25	07/25		Non-specific Declare and participate
Liz Sherwin	Committee member – Clinical Oncologist	Direct-financial	Paid host of Novartis sponsored evening educational meeting discussing role of adjuvant ribociclib. Relevant to breast cancer but not topic under consideration.	09/25	11/25	09/25	Non-specific Declare and participate